Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.09.13	Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014 (Businesswire)
17.09.13	Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome (Businesswire)
09.09.13	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
30.08.13	Ipsen: Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013 (Businesswire)
30.08.13	Ipsen: 2013 Half-Year Results and Financial Objectives (Businesswire)
06.08.13	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
15.07.13	Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology (Businesswire)
15.07.13	Ipsen Announce a Sponsored Research Agreement with Harvard Medical School to Discover Novel Engineered Botulinum Toxins for Serious Neurologic Diseases (Businesswire)
11.07.13	Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs”)1 (Businesswire)
09.07.13	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
09.07.13	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.02.13	Eziclen® / Izinova® a New Product for Bowel Cleansing Successfully Completed European Decentralised Registration Procedure (Businesswire)
17.01.13	Teijin Pharma to Launch Ipsen's Somatuline® Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan (Businesswire)
07.01.13	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
07.01.13	Ipsen S.A. : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.01.13	Ipsen's Corporate Agenda for 2013 (Businesswire)
18.12.12	Oncodesign And the Laboratory for Neurobiology and Gene Therapy at The KU Leuven Enter into a Research Collaboration for Advancing Drug Discovery Efforts with Ipsen in Parkinson's Disease (Businesswire)
10.12.12	Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer (Businesswire)
06.12.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
03.12.12	Ipsen and Galderma increase their collaboration for Dysport® in new territories (Businesswire)
20.11.12	Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A (Businesswire)
09.11.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
31.10.12	Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection (Businesswire)
29.10.12	Ipsen’s third quarter and first nine months 2012 sales (Businesswire)
23.10.12	Ipsen US Awards up to $300,000 for Dystonia Fellowship Grants in 2013 (Businesswire)
19.10.12	Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications (Businesswire)
05.10.12	IPSEN SA: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.10.12	Ipsen initiates a phase II "Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod (Businesswire)
03.10.12	Ipsen Provides Update on Recent Agreement with Inspiration (Businesswire)
01.10.12	Tasquinimod Biomarker Phase II data presented at ESMO 2012 (Businesswire)
10.09.12	Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US (Businesswire)
07.09.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
28.08.12	Ipsen's Half-Year 2012 Results (Businesswire)
21.08.12	Ipsen and Inspiration Biopharmaceuticals Renegotiate Strategic Partnership Agreement (Businesswire)
02.08.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
11.07.12	Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope (Businesswire)
10.07.12	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
10.07.12	Ipsen’s Partner Inspiration Biopharmaceuticals Announces Hold of Phase III Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Hemophilia B (Businesswire)
06.07.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
29.06.12	Ipsen’s Somatuline® Receives Marketing Approval in Japan for the Treatment of Acromegaly and Pituitary Gigantism (Businesswire)
05.06.12	IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
04.06.12	Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer (Businesswire)
01.06.12	Combined Shareholders’ Meeting of IPSEN S.A. Held on 1 June 2012 (Businesswire)
21.05.12	600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders’ Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders’ Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten